University of New South Wales, Liverpool Hospital, Liverpool, New South Wales 2170, Australia; Department of Nuclear Medicine and PET, Liverpool Hospital, Liverpool, New South Wales 2170, Australia.
Clin Imaging. 2013 Nov-Dec;37(6):1084-8. doi: 10.1016/j.clinimag.2013.07.011. Epub 2013 Sep 12.
To compare 123I-metaiodobenzylguanidine (MIBG) and [Fluorine-18]-2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) in 22 patients with phaeochromocytomas and paragangliomas (PGL) retrospectively and to evaluate the correlation between FDG uptake and Ki-67 proliferative index. Fourteen of 17 (82%) patients at initial diagnosis had positive FDG uptake, more intensely in PGL. Eleven of 12 (92%) patients had positive MIBG uptake. PET and MIBG scintigraphy were concordant in 10 patients, discordant in 6. Combined results yielded no false negative findings and are complementary. Neither maximum standardised uptake value nor visual scores on MIBG correlated with Ki-67.
回顾性比较 22 例嗜铬细胞瘤和副神经节瘤（PGL）患者的 123I-间碘苄胍（MIBG）和 [氟-18]-2-氟-2-脱氧-D-葡萄糖（FDG）正电子发射断层扫描（PET），并评估 FDG 摄取与 Ki-67 增殖指数之间的相关性。17 例初诊患者中有 14 例（82%）FDG 摄取阳性，PGL 摄取更强烈。12 例患者中有 11 例（92%）MIBG 摄取阳性。10 例患者的 PET 和 MIBG 闪烁扫描结果一致，6 例不一致。联合结果无假阴性发现且互补。MIBG 的最大标准化摄取值或视觉评分均与 Ki-67 无相关性。
